Specific depressive symptoms predict remission to aripiprazole augmentation in late‐life treatment resistant depression

Gebara, Marie Anne; DiNapoli, Elizabeth A.; Kasckow, John; Karp, Jordan F.; Blumberger, Daniel M.; Lenze, Eric J.; Mulsant, Benoit H.; Reynolds, Charles F.

doi:10.1002/gps.4813

Cited by 7 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specific symptom predictors: Four studies assessed additional individual items on the HAMD and Montgomery and Asberg Depression Rating Scale as predictors of response and remission for lithium (Álvarez et al, 1997; Joffe et al, 1993), T3 (Agid and Lerer, 2003; Joffe et al, 1993) and aripiprazole (Gebara et al, 2018). Higher depressive psychomotor activity scores predicted lithium remission (Álvarez et al, 1997) and less sleep disturbance predicted lithium and T3 response (Agid and Lerer, 2003; Joffe et al, 1993).…”

Section: Resultsmentioning

confidence: 99%

“…Higher depressive psychomotor activity scores predicted lithium remission (Álvarez et al, 1997) and less sleep disturbance predicted lithium and T3 response (Agid and Lerer, 2003; Joffe et al, 1993). Less apparent sadness and inability to feel and higher sleep disturbance were predictive of aripiprazole remission (Gebara et al, 2018). Greater genital symptoms and diurnal variation were associated with T3 response (Agid and Lerer, 2003).…”

Section: Resultsmentioning

confidence: 99%

“…Aripiprazole Quetiapine OFC Barbee et al, 2004Casey et al, 2012Gebara et al, 2018Muzina et al, 2011Steffens et al, 2011Schaffer et al, 2013 McIntyre et al, Eller et al, 2009Woo et al, 2013Iosifescu et al, 2008Joffe et al, 1993Agid and Lerer, 2003Rizvi et al, 2014Rasgon et al, 2016Yoshimura et al, 2014 Depression Eller et al, 2009Woo et al, 2013Iosifescu et al, 2008Joffe et al, 1993Agid and Lerer, 2003Rizvi et al, 2014Rasgon et al, 2016Yoshimura et al, 2014 Biological predictive of response. Takahashi et al (2014) reported that several domains on the Neuroticism-Extraversion-Openness scale and the Temperame...…”

Section: Clinical and Sociodemographic Predictorsmentioning

confidence: 99%

See 2 more Smart Citations

Predictors of response to augmentation treatment in patients with treatment-resistant depression: A systematic review

et al. 2019

View full text Add to dashboard Cite

Background: Treatment-resistant depression is an important contributor to the global burden of depression. Antidepressant augmentation is a recommended treatment strategy for treatment-resistant patients, but outcomes remain poor. Identifying factors that are predictive of response to augmentation treatments may improve outcomes. Aims: This review aimed to synthesise the existing literature examining predictors of response to augmentation treatments in patients who had insufficiently responded to initial treatment. Methods: A systematic search was conducted identifying 2241 unique manuscripts. 24 examining predictors of outcome to pharmacological or psychological augmentation treatment were included in this review. Results: Atypical antipsychotics were the most frequently assessed treatment class (nine studies), closely followed by mood stabilisers (eight studies). Only one eligible psychological augmentation study was identified. Early response to treatment (week 2) was the best-supported predictor of subsequent treatment outcome, reported by six studies. Many predictor variables were only assessed by one report and others such as pre-treatment severity yielded contradictory results, both within and across treatment classes. Conclusions: This review highlights the importance of early response as a predictor of pharmacological augmentation outcome, with implications for both the monitoring and treatment of resistant unipolar patients. Further replication is needed across specific interventions to fully assess the generalisability of this finding. However, the clear lack of consistent evidence for other predictive factors both within and across treatments, and the scarce examination of psychological augmentation, demonstrates the need for much more research of a high quality if response prediction is to improve outcomes for patients with treatment-resistant depression.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Clinical and Sociodemographic Predictorsmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of response to augmentation treatment in patients with treatment-resistant depression: A systematic review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Предиктором плохого ответа на терапию было наличие болевых синдромов и выраженной социально-трудовой дезадаптации. В исследованиях, где оценивались клинические особенности пациентов с хорошим ответом на лечение арипипразолом, препарат был особенно эффективен у пожилых пациентов с нарушениями сна, жалобами на отсутствие интересов, но без переживания витальной тоски [34]. В других работах со схожим дизайном предикторами полноценного ответа на терапию также были хорошее состояние физического здоровья, более высокие результаты при когнитивном тестировании, наличие суицидальных мыслей и ажитация, а предикторами плохого ответа -наличие болевых синдромов и жалобы на снижение продуктивности в работе [35,36].…”

Section: Introductionunclassified

Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study

Олейчик¹,

Баранов²,

Shishkovskaya³

2023

Psychiatry

View full text Add to dashboard Cite

Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identiﬁed as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efﬁcacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efﬁcacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efﬁcacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efﬁcacy in augmentation of antidepressant therapy and has a favorable tolerability proﬁle. The maximum efﬁcacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.

show abstract

A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult

Blaszczyk,

Mathys,

2023

Drugs Aging

View full text Add to dashboard Cite

Specific depressive symptoms predict remission to aripiprazole augmentation in late‐life treatment resistant depression

Cited by 7 publications

References 20 publications

Predictors of response to augmentation treatment in patients with treatment-resistant depression: A systematic review

Predictors of response to augmentation treatment in patients with treatment-resistant depression: A systematic review

Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study

A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult

Contact Info

Product

Resources

About